Precision medicine for hepatocellular carcinoma: driver mutations and targeted therapy

Hepatocellular carcinoma (HCC) is the third most frequent cause of tumor-related mortality and there are an estimated approximately 850,000 new cases annually. Most HCC patients are diagnosed at middle or advanced stage, losing the opportunity of surgery. The development of HCC is promoted by accumu...

Descripción completa

Detalles Bibliográficos
Autores principales: Ding, Xiao-Xiao, Zhu, Qing-Ge, Zhang, Shi-Ming, Guan, Lei, Li, Ting, Zhang, Lei, Wang, Shi-Yang, Ren, Wan-Li, Chen, Xue-Mei, Zhao, Jing, Lin, Song, Liu, Zhi-Zhen, Bai, Yan-Xia, He, Bing, Zhang, Hu-Qin
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Impact Journals LLC 2017
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5589693/
https://www.ncbi.nlm.nih.gov/pubmed/28903454
http://dx.doi.org/10.18632/oncotarget.18382

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5589693/
https://www.ncbi.nlm.nih.gov/pubmed/28903454
http://dx.doi.org/10.18632/oncotarget.18382

Ejemplares similares